Peng Wu
Peng Wu
確認したメール アドレス: mit.edu - ホームページ
タイトル
引用先
引用先
FDA-approved small-molecule kinase inhibitors
P Wu, TE Nielsen, MH Clausen
Trends in pharmacological sciences 36 (7), 422-439, 2015
7892015
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
P Wu, TE Nielsen, MH Clausen
Drug discovery today 21 (1), 5-10, 2016
4022016
Allosteric small-molecule kinase inhibitors
P Wu, MH Clausen, TE Nielsen
Pharmacology & therapeutics 156, 59-68, 2015
1452015
Scaffold Diversity from N-Acyliminium Ions
P Wu, TE Nielsen
Chemical reviews 117 (12), 7811-7856, 2017
1112017
PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress
P Wu, YZ Hu
Current medicinal chemistry 17 (35), 4326-4341, 2010
1082010
A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9
B Maji, SA Gangopadhyay, M Lee, M Shi, P Wu, R Heler, B Mok, D Lim, ...
Cell 177 (4), 1067-1079. e19, 2019
812019
Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities
W Huang, L Tang, Y Shi, S Huang, L Xu, R Sheng, P Wu, J Li, N Zhou, ...
Bioorganic & medicinal chemistry 19 (23), 7158-7167, 2011
782011
Reactivity and synthetic applications of multicomponent Petasis reactions
P Wu, M Givskov, TE Nielsen
Chemical reviews 119 (20), 11245-11290, 2019
762019
Small molecules targeting phosphoinositide 3-kinases
P Wu, Y Hu
MedChemComm 3 (11), 1337-1355, 2012
702012
Dual-target-directed 1, 3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer’s disease
W Huang, D Lv, H Yu, R Sheng, SC Kim, P Wu, K Luo, J Li, Y Hu
Bioorganic & medicinal chemistry 18 (15), 5610-5615, 2010
612010
Clinical and marketed proteasome inhibitors for cancer treatment
J Zhang, P Wu, Y Hu
Current medicinal chemistry 20 (20), 2537-2551, 2013
532013
PI3K inhibitors for cancer therapy: what has been achieved so far?
P Wu, T Liu, Y Hu
Current medicinal chemistry 16 (8), 916-930, 2009
502009
Synthesis, biological evaluation and quantitative structure-activities relationship of flavonoids as vasorelaxant agents
X Dong, T Liu, J Yan, P Wu, J Chen, Y Hu
Bioorganic & medicinal chemistry 17 (2), 716-726, 2009
492009
Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl) quinoxalines as PI3Kα inhibitors
P Wu, Y Su, X Liu, L Zhang, Y Ye, J Xu, S Weng, Y Li, T Liu, S Huang, ...
European journal of medicinal chemistry 46 (11), 5540-5548, 2011
302011
Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors
X Lv, H Ying, X Ma, N Qiu, P Wu, B Yang, Y Hu
European journal of medicinal chemistry 99, 36-50, 2015
272015
Discovery of novel 2-piperidinol-3-(arylsulfonyl) quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors
P Wu, Y Su, X Liu, B Yang, Q He, Y Hu
Bioorganic & medicinal chemistry 20 (9), 2837-2844, 2012
222012
Flavonoids as vasorelaxant agents: synthesis, biological evaluation and quantitative structure activities relationship (QSAR) studies
X Dong, Y Wang, T Liu, P Wu, J Gao, J Xu, B Yang, Y Hu
Molecules 16 (10), 8257-8272, 2011
222011
Inhibition of RNA-binding proteins with small molecules
P Wu
Nature Reviews Chemistry 4 (9), 441-458, 2020
192020
Discovery of novel morpholino–quinoxalines as PI3Kα inhibitors by pharmacophore-based screening
P Wu, Y Su, X Liu, J Yan, Y Ye, L Zhang, J Xu, S Weng, Y Li, T Liu, ...
MedChemComm 3 (6), 659-662, 2012
192012
Phosphorylation-inducing chimeric small molecules
SU Siriwardena, DNP Munkanatta Godage, VM Shoba, S Lai, M Shi, ...
Journal of the American Chemical Society 142 (33), 14052-14057, 2020
182020
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20